N@N

6-month results from EVEREST study evaluating Visudyne(R) therapy in patients with polypoidal choroidal vasculopathy

^{Published on 2009-12-09 04:12:02 - Market Wire}
 

 - Complete Polyp Regression (primary endpoint): Visudyne combination with Lucentis and Visudyne monotherapy showed a significantly higher proportion of patients with complete polyp regression at month 6 than the Lucentis monotherapy group. Complete polyp regression was achieved in 77.8% of patients who received the Visudyne - Lucentis combination, while 71.4% of Visudyne monotherapy patients had complete regression compared with 28.6% of patients in the Lucentis monotherapy group (p=0.0018 for combination, p=0.0037 for Visudyne vs. Lucentis). - Best Corrected Visual Acuity from baseline to Month 6: On average, patients in all groups gained vision, with patients in the combination group achieving the highest gain (+10.9 letters from baseline). Lucentis monotherapy patients gained +9.2 letters, and Visudyne monotherapy patients +7.5 letters. Differences between the groups are not statistically significant. - All therapies were well tolerated and the safety findings were consistent with the established safety profiles of Visudyne and Lucentis. 

 - Visudyne + Lucentis combination (n=19) or - Visudyne monotherapy (n=21) or - Lucentis monotherapy (n=21)